Non small cell lung cancer management: Difference between revisions

Jump to navigation Jump to search
(Created page with "__NOTOC__ {{Non small cell lung cancer}} {{CMG}}; {{AE}} {{Alonso}} {{MV}} ==Overview== ==Management Approach== *The table below summarizes the different standard treatment...")
 
 
(10 intermediate revisions by 3 users not shown)
Line 1: Line 1:
__NOTOC__
__NOTOC__
{{Non small cell lung cancer}}
{{Non small cell lung cancer}}
{{CMG}}; {{AE}} {{Alonso}} {{MV}}
{{CMG}}; {{AE}}{{MV}}


==Overview==
==Overview==


The optimal management approach of non-small cell lung cancer will depend on a series of characteristics, that include: pre-treatment evaluation, location, and adequate [[Cancer staging|staging]]. Common treatment options for management of non-small cell lung cancer include [[surgery]], [[neoadjuvant chemotherapy]], [[Adjuvant therapy|adjuvant chemotherapy]], and [[radiation therapy]].


==Management Approach==
==Management Approach==
*The table below summarizes the different standard treatment options according to the TNM criteria for non-small cell lung cancer
*The table below summarizes the different standard treatment options according to the TNM criteria for non-small cell lung cancer.<ref name="PDQ"> PDQ Adult Treatment Editorial Board. http://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0032637/ Accessed on February 22, 2016 </ref> <small>To have a detailed information on the sequential management please click on each TNM stage in the table.</small>


{|style="border: 5px; font-size: 90%; margin: 5px; width: 1000px" align=center
{| style="border: 5px; font-size: 90%; margin: 5px; width: 1000px" align="center"
!style="padding: 5px 5px; background: #4479BA; font-weight: bold; text-align:center;" colspan="3"|{{fontcolor|#FFF|'''Standard Treatment Options'''<br><SMALL>Adapted from Non-Small Cell Lung Cancer Treatment (PDQ® 2016) <ref name="PDQ"> PDQ Adult Treatment Editorial Board. http://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0032637/ Accessed on February 22, 2016 </ref></SMALL>}}
! style="padding: 5px 5px; background: #4479BA; font-weight: bold; text-align:center;" colspan="3" |{{fontcolor|#FFF|'''Standard Treatment Options'''<br><SMALL>Adapted from Non-Small Cell Lung Cancer Treatment (PDQ® 2016) <ref name="PDQ"> PDQ Adult Treatment Editorial Board. http://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0032637/ Accessed on February 22, 2016 </ref></SMALL>}}
|+
|+
|-
|-
Line 16: Line 17:
! style="background: #4479BA; width: 100px;" | {{fontcolor|#FFF|'''Standard Treatment Options'''}}
! style="background: #4479BA; width: 100px;" | {{fontcolor|#FFF|'''Standard Treatment Options'''}}
|-
|-
|style="padding: 5px 5px; background: #DCDCDC; font-weight: bold; text-align:center;"| '''Occult'''
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold; text-align:center;" | '''[[Non small cell lung cancer medical therapy stage I|Stages IA and IB]]'''
|style="padding: 5px 5px; background: #F5F5F5;"| 
| style="padding: 5px 5px; background: #F5F5F5;" |   
* Surgery
|-
|style="padding: 5px 5px; background: #DCDCDC; font-weight: bold; text-align:center;"| '''Stage 0'''
|style="padding: 5px 5px; background: #F5F5F5;"| 
*Surgery
*Endobronchial therapies
|-
|style="padding: 5px 5px; background: #DCDCDC; font-weight: bold; text-align:center;"| '''Stages IA and IB'''
|style="padding: 5px 5px; background: #F5F5F5;"|   
*Surgery
*Surgery
*Radiation therapy
*Radiation therapy
*IB,  if the tumor is >4cm,  surgery and chemotherapy
*IB,  if the tumor is >4cm,  surgery and chemotherapy
|-
|-
|style="padding: 5px 5px; background: #DCDCDC; font-weight: bold; text-align:center;"|'''Stages IIA and IIB'''
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold; text-align:center;" |'''[[Non small cell lung cancer medical therapy stage II|Stages IIA and IIB]]'''
|style="padding: 5px 5px; background: #F5F5F5;"|   
| style="padding: 5px 5px; background: #F5F5F5;" |   
*Surgery
*Surgery
*Neoadjuvant chemotherapy
*Neoadjuvant chemotherapy
Line 38: Line 30:
*Radiation therapy
*Radiation therapy
|-
|-
|style="padding: 5px 5px; background: #DCDCDC; font-weight: bold; text-align:center;"| '''Stage IIIA'''
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold; text-align:center;" | '''[[Non small cell lung cancer medical therapy stage III|Stage IIIA]]'''
|style="padding: 5px 5px; background: #F5F5F5;"|   
| style="padding: 5px 5px; background: #F5F5F5;" |   
'''Resected or resectable disease'''
'''Resected or resectable disease'''
*Surgery
*Surgery
Line 58: Line 50:
*Chemotherapy combined with radiation therapy and/or surgery
*Chemotherapy combined with radiation therapy and/or surgery
|-
|-
|style="padding: 5px 5px; background: #DCDCDC; font-weight: bold; text-align:center;"| '''Stage IIIB'''
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold; text-align:center;" | '''[[Non small cell lung cancer medical therapy stage III|Stage IIIB]]'''
|style="padding: 5px 5px; background: #F5F5F5;"|   
| style="padding: 5px 5px; background: #F5F5F5;" |   
*Sequential or concurrent chemotherapy and radiation therapy
*Sequential or concurrent chemotherapy and radiation therapy
*Chemotherapy followed by surgery (for selected patients)
*Chemotherapy followed by surgery (for selected patients)
*Radiation therapy alone
*Radiation therapy alone
|-
|-
|style="padding: 5px 5px; background: #DCDCDC; font-weight: bold; text-align:center;"| '''Stage IV'''
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold; text-align:center;" | '''[[Non small cell lung cancer medical therapy stage IV|Stage IV]]'''
|style="padding: 5px 5px; background: #F5F5F5;"|   
| style="padding: 5px 5px; background: #F5F5F5;" |   
*Cytotoxic combination chemotherapy (first line)
*Cytotoxic combination chemotherapy (first line)
*Combination chemotherapy with bevacizumab or cetuximab
*Combination chemotherapy with bevacizumab or cetuximab
Line 75: Line 67:
* External-beam radiation therapy (primarily for palliation of local symptomatic tumor growth)
* External-beam radiation therapy (primarily for palliation of local symptomatic tumor growth)
|-
|-
|style="padding: 5px 5px; background: #DCDCDC; font-weight: bold; text-align:center;"| '''Recurrent'''
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold; text-align:center;" | '''Recurrent'''
|style="padding: 5px 5px; background: #F5F5F5;"|   
| style="padding: 5px 5px; background: #F5F5F5;" |   
*Radiation therapy (for palliation)
*Radiation therapy (for palliation)
*Chemotherapy or kinase inhibitors alone EGFR inhibitors in patients with/without EGFR mutations
*Chemotherapy or kinase inhibitors alone EGFR inhibitors in patients with/without EGFR mutations
Line 92: Line 84:
[[Category:Pulmonology]]
[[Category:Pulmonology]]
[[Category:Lung cancer]]
[[Category:Lung cancer]]
[[Category:Up-To-Date]]
[[Category:Oncology]]
[[Category:Medicine]]
[[Category:Pulmonology]]
[[Category:Surgery]]

Latest revision as of 22:22, 23 February 2018

Non Small Cell Lung Cancer Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Non Small Cell Lung Cancer from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X-Ray

CT Scan

MRI

Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Management Approach

Stage I
Stage II
Stage III
Stage IV
Metastatic Cancer

Medical Therapy

Chemotherapy
Radiation Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Non small cell lung cancer management On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Non small cell lung cancer management

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Non small cell lung cancer management

CDC on Non small cell lung cancer management

Non small cell lung cancer management in the news

Blogs on Non small cell lung cancer management

Directions to Hospitals Treating Non small cell carcinoma of the lung

Risk calculators and risk factors for Non small cell lung cancer management

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Maria Fernanda Villarreal, M.D. [2]

Overview

The optimal management approach of non-small cell lung cancer will depend on a series of characteristics, that include: pre-treatment evaluation, location, and adequate staging. Common treatment options for management of non-small cell lung cancer include surgery, neoadjuvant chemotherapy, adjuvant chemotherapy, and radiation therapy.

Management Approach

  • The table below summarizes the different standard treatment options according to the TNM criteria for non-small cell lung cancer.[1] To have a detailed information on the sequential management please click on each TNM stage in the table.
Standard Treatment Options
Adapted from Non-Small Cell Lung Cancer Treatment (PDQ® 2016) [1]
Stage (TNM criteria) Standard Treatment Options
Stages IA and IB
  • Surgery
  • Radiation therapy
  • IB, if the tumor is >4cm, surgery and chemotherapy
Stages IIA and IIB
  • Surgery
  • Neoadjuvant chemotherapy
  • Adjuvant chemotherapy
  • Radiation therapy
Stage IIIA

Resected or resectable disease

  • Surgery
  • Neoadjuvant therapy
  • Adjuvant therapy

Unresectable disease

  • Radiation therapy
  • Chemoradiation therapy

Superior sulcus tumors

  • Radiation therapy alone
  • Radiation therapy and surgery
  • Concurrent chemotherapy with radiation therapy and surgery
  • Surgery alone (for selected patients)

Tumors that invade the chest wall

  • Surgery
  • Surgery and radiation therapy
  • Radiation therapy alone
  • Chemotherapy combined with radiation therapy and/or surgery
Stage IIIB
  • Sequential or concurrent chemotherapy and radiation therapy
  • Chemotherapy followed by surgery (for selected patients)
  • Radiation therapy alone
Stage IV
  • Cytotoxic combination chemotherapy (first line)
  • Combination chemotherapy with bevacizumab or cetuximab
  • EGFR tyrosine kinase inhibitors (first line)
  • EML4-ALK inhibitors in patients with EML-ALK translocations
  • Immune checkpoint inhibition with nivolumab for selected patients with squamous or nonsquamous metastatic

Maintenance therapy following first-line chemotherapy

  • Endobronchial laser therapy and/or brachytherapy (for obstructing lesions)
  • External-beam radiation therapy (primarily for palliation of local symptomatic tumor growth)
Recurrent
  • Radiation therapy (for palliation)
  • Chemotherapy or kinase inhibitors alone EGFR inhibitors in patients with/without EGFR mutations
  • EML4-ALK inhibitors in patients with EML-ALK translocations
  • Surgical resection of isolated cerebral metastasis (for highly selected patients)
  • Laser therapy or interstitial radiation therapy (for endobronchial lesions)
  • Stereotactic radiation surgery (for highly selected patients)

References

  1. 1.0 1.1 PDQ Adult Treatment Editorial Board. http://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0032637/ Accessed on February 22, 2016